Gene Therapy Market Report: Trends, Forecast and Competitive Analysis
Get it in 2 to 4 weeks by ordering today
The future of the global gene therapy market looks promising with opportunities in the oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, and infectious disease. The global gene therapy market is expected to grow with a CAGR of 27%-29% from 2020 to 2025. The major drivers for this market are increasing government support for R&D activities, rising awareness of people towards gene therapy, and increasing prevalence of cancer.
A total of XX figures / charts and XX tables are provided in this more than 150-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global gene therapy market report, please download the report brochure.
In this market, non-viral vectors is the largest vector of gene therapy, whereas oncological disorder is the largest application. Growth in various segments of the gene therapy market are given below:
The study includes trends and forecast for the global gene therapy market by gene type, application, vector, indication, delivery method, and region as follows:
By Gene Type [Value ($ Million) shipment analysis for 2014 – 2025]:
Lucintel forecasts that non-viral vectors will remain the largest segment over the forecast period due to increasing demand of oligonucleotide-based non-viral vector gene therapies and advancements in physicochemical approaches for gene therapies during preclinical and clinical trials.
Within this market, oncological disorder will remain the largest segment by application over the forecast period due to increasing prevalance of cancer.
North America will remain the largest region over the forecast period due to high disposable incomes, increasing prevalance of chronic diseases, and growing healthcare expenditure in the region.
Features of the Global Gene Therapy Market
Q.1 What are some of the most promising potential, high-growth opportunities for the global gene therapy market by gene type (antigen, cytokine, tumor suppressor, suicide, deficiency, growth factors, receptors, and others), application (oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, infectious disease, and other diseases), vector (non-viral vectors (oligonucleotides and other non-viral vectors) and viral vectors (retroviral vectors, adeno-associated virus vectors, and other viral vectors)), indication (neurological diseases, cancer, hepatological diseases, duchenne muscular dystrophy, and other indications), delivery method (in vivo gene therapy and ex vivo gene therapy), and region (North America, Europe, Asia Pacific, and Rest of the World)?
Q.2 Which segments will grow at a faster pace and why?
Q.3 Which region will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global gene therapy market?
Q.5 What are the business risks and threats to the global gene therapy market?
Q.6 What are the emerging trends in this gene therapy market and the reasons behind them?
Q.7 What are some changing demands of customers in this gene therapy market?
Q.8 What are the new developments in this gene therapy market? Which companies are leading these developments?
Q.9 Who are the major players in this gene therapy market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in this gene therapy market, and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M&A activities did take place in the last five years in the global gene therapy market?
Report Scope
Key Features Description
Base Year for Estimation 2019
Trend Period
(Actual Estimates) 2014-2019
Forecast Period 2020-2025
Pages More than 150
Market Representation / Units Revenue in US $ Million
Report Coverage Market Trends & Forecasts, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Venture, and Company Profiling
Market Segments Gene Type (Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others), Application (Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Disease, and Other Diseases), Vector (Non-Viral Vectors and Viral Vectors), Indication (Neurological Diseases, Cancer, Hepatological Diseases, Duchenne Muscular Dystrophy, and Other Indications), and Delivery Method (In Vivo Gene Therapy and Ex Vivo Gene Therapy)
Regional Scope North America (USA, Mexico, and Canada), Europe (United Kingdom, Spain, Germany, and France), Asia (China, India, and Japan), and ROW (Brazil)
Customization 10% Customization without Any Additional Cost
The future of the global gene therapy market looks promising with opportunities in the oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, and infectious disease. The global gene therapy market is expected to grow with a CAGR of 27%-29% from 2020 to 2025. The major drivers for this market are increasing government support for R&D activities, rising awareness of people towards gene therapy, and increasing prevalence of cancer.
A total of XX figures / charts and XX tables are provided in this more than 150-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global gene therapy market report, please download the report brochure.
In this market, non-viral vectors is the largest vector of gene therapy, whereas oncological disorder is the largest application. Growth in various segments of the gene therapy market are given below:
The study includes trends and forecast for the global gene therapy market by gene type, application, vector, indication, delivery method, and region as follows:
By Gene Type [Value ($ Million) shipment analysis for 2014 – 2025]:
- Antigen
- Cytokine
- Tumor Suppressor
- Suicide
- Deficiency
- Growth Factors
- Receptors
- Others
- Oncological Disorders
- Rare Diseases
- Cardiovascular Diseases
- Neurological Disorders
- Infectious Disease
- Other Diseases
- Non-Viral Vectors
- Oligonucleotides
- Other Non-Viral Vectors
- Viral Vectors
- Retroviral Vectors
- Adeno-Associated Virus Vectors
- Other Viral Vectors
- Neurological Diseases
- Cancer
- Hepatological Diseases
- Duchenne Muscular Dystrophy
- Other Indications
- In Vivo Gene Therapy
- Ex Vivo Gene Therapy
- North America
- United States
- Canada
- Mexico
- Europe
- United Kingdom
- Germany
- France
- Asia Pacific
- China
- India
- Japan
- The Rest of the World
- Brazil
Lucintel forecasts that non-viral vectors will remain the largest segment over the forecast period due to increasing demand of oligonucleotide-based non-viral vector gene therapies and advancements in physicochemical approaches for gene therapies during preclinical and clinical trials.
Within this market, oncological disorder will remain the largest segment by application over the forecast period due to increasing prevalance of cancer.
North America will remain the largest region over the forecast period due to high disposable incomes, increasing prevalance of chronic diseases, and growing healthcare expenditure in the region.
Features of the Global Gene Therapy Market
- Market Size Estimates: Global gene therapy market size estimation in terms of value ($M) shipment.
- Trend and Forecast Analysis: Market trends (2014-2019) and forecast (2020-2025) by various segments.
- Segmentation Analysis: Global gene therapy market size by various segments, such as gene type, application, vector, indication, and delivery method in terms of value.
- Regional Analysis: Global gene therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different gene type, application, vector, indication, delivery method, and region for the global gene therapy market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the global gene therapy market.
- Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
Q.1 What are some of the most promising potential, high-growth opportunities for the global gene therapy market by gene type (antigen, cytokine, tumor suppressor, suicide, deficiency, growth factors, receptors, and others), application (oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, infectious disease, and other diseases), vector (non-viral vectors (oligonucleotides and other non-viral vectors) and viral vectors (retroviral vectors, adeno-associated virus vectors, and other viral vectors)), indication (neurological diseases, cancer, hepatological diseases, duchenne muscular dystrophy, and other indications), delivery method (in vivo gene therapy and ex vivo gene therapy), and region (North America, Europe, Asia Pacific, and Rest of the World)?
Q.2 Which segments will grow at a faster pace and why?
Q.3 Which region will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global gene therapy market?
Q.5 What are the business risks and threats to the global gene therapy market?
Q.6 What are the emerging trends in this gene therapy market and the reasons behind them?
Q.7 What are some changing demands of customers in this gene therapy market?
Q.8 What are the new developments in this gene therapy market? Which companies are leading these developments?
Q.9 Who are the major players in this gene therapy market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in this gene therapy market, and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M&A activities did take place in the last five years in the global gene therapy market?
Report Scope
Key Features Description
Base Year for Estimation 2019
Trend Period
(Actual Estimates) 2014-2019
Forecast Period 2020-2025
Pages More than 150
Market Representation / Units Revenue in US $ Million
Report Coverage Market Trends & Forecasts, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Venture, and Company Profiling
Market Segments Gene Type (Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others), Application (Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Disease, and Other Diseases), Vector (Non-Viral Vectors and Viral Vectors), Indication (Neurological Diseases, Cancer, Hepatological Diseases, Duchenne Muscular Dystrophy, and Other Indications), and Delivery Method (In Vivo Gene Therapy and Ex Vivo Gene Therapy)
Regional Scope North America (USA, Mexico, and Canada), Europe (United Kingdom, Spain, Germany, and France), Asia (China, India, and Japan), and ROW (Brazil)
Customization 10% Customization without Any Additional Cost
1. EXECUTIVE SUMMARY
2. MARKET BACKGROUND AND CLASSIFICATIONS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2014 T 2025
3.1: Macroeconomic Trends and Forecast
3.2: Global Gene Therapy Market Trends and Forecast
3.3: Global Gene Therapy Market by Gene Type
3.3.1: Antigen
3.3.2: Cytokine
3.3.3: Tumor Suppressor
3.3.4: Suicide
3.3.5: Deficiency
3.3.6: Growth Factors
3.3.7: Receptors
3.3.8: Others
3.4. Global Gene Therapy Market by Application
3.4.1: Oncological Disorders
3.4.2: Rare Diseases
3.4.3: Cardiovascular Diseases
3.4.4: Neurological Disorders
3.4.5: Infectious Disease
3.4.6: Other Diseases
3.5. Global Gene Therapy Market by Vector
3.5.1: Non-Viral Vectors
3.5.1.1: Oligonucleotides
3.5.1.2: Other Non-Viral Vectors
3.5.2: Viral Vectors
3.5.2.1: Retroviral Vectors
3.5.2.2: Adeno-Associated Virus Vectors
3.5.2.3: Other Viral Vectors
3.6. Global Gene Therapy Market by Indication
3.6.1: Neurological Diseases
3.6.2: Cancer
3.6.3: Hepatological Diseases
3.6.4: Duchenne Muscular Dystrophy
3.6.5: Other Indications
3.7. Global Gene Therapy Market by Delivery Method
3.7.1: In Viv Gene Therapy
3.7.2: Ex Viv Gene Therapy
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION
4.1: Global Gene Therapy Market by Region
4.2: North American Gene Therapy Market
4.2.1: Market by Gene Type: Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others
4.2.2: Market byApplication: Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Disease, and Other Diseases
4.2.3: Market by Vector: Non-Viral Vectors (Oligonucleotides and Other Non-Viral Vectors) and Viral Vectors (Retroviral Vectors, Adeno-Associated Virus Vectors, and Other Viral Vectors
4.2.4: Market by Indication: Neurological Diseases, Cancer, Hepatological Diseases, Duchenne Muscular Dystrophy, and Other Indications
4.2.5: Market by Delivery Method: In Viv Gene Therapy and Ex Viv Gene Therapy
4.2.6: The United States Gene Therapy Market
4.2.7: The Canadian Gene Therapy Market
4.2.8: The Mexican Gene Therapy Market
4.3. European Gene Therapy Market
4.3.1: Market by Gene Type: Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others
4.3.2: Market by Application: Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Disease, and Other Diseases
4.3.3: Market by Vector: Non-Viral Vectors (Oligonucleotides and Other Non-Viral Vectors) and Viral Vectors (Retroviral Vectors, Adeno-Associated Virus Vectors, and Other Viral Vectors
4.3.4: Market by Indication: Neurological Diseases, Cancer, Hepatological Diseases, Duchenne Muscular Dystrophy, and Other Indications
4.3.5: Market by Delivery Method: In Viv Gene Therapy and Ex Viv Gene Therapy
4.3.6: The Gene Therapy Market of United Kingdom
4.3.7: The German Gene Therapy Market
4.3.8: The French Gene Therapy Market
4.4. APAC Gene Therapy Market
4.4.1: Market by Gene Type: Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others
4.4.2: Market byApplication: Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Disease, and Other Diseases
4.4.3: Market by Vector: Non-Viral Vectors (Oligonucleotides and Other Non-Viral Vectors) and Viral Vectors (Retroviral Vectors, Adeno-Associated Virus Vectors, and Other Viral Vectors
4.4.4: Market by Indication: Neurological Diseases, Cancer, Hepatological Diseases, Duchenne Muscular Dystrophy, and Other Indications
4.4.5: Market by Delivery Method: In Viv Gene Therapy and Ex Viv Gene Therapy
4.4.6: The Chinese Gene Therapy Market
4.4.7: The Indian Gene Therapy Market
4.4.8: The Japanese Gene Therapy Market
4.5: ROW Gene Therapy Market
4.5.1: Market by Gene Type: Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others
4.5.2: Market by Application: Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Disease, and Other Diseases
4.5.3: Market by Vector: Non-Viral Vectors (Oligonucleotides and Other Non-Viral Vectors) and Viral Vectors (Retroviral Vectors, Adeno-Associated Virus Vectors, and Other Viral Vectors
4.5.4: Market by Indication: Neurological Diseases, Cancer, Hepatological Diseases, Duchenne Muscular Dystrophy, and Other Indications
4.5.5: Market by Delivery Method: In Viv Gene Therapy and Ex Viv Gene Therapy
4.5.6: Brazilian Gene Therapy Market
5. COMPETITOR ANALYSIS
5.1: Market Share Analysis
5.2: Product Portfoli Analysis
5.3: Operational Integration
5.4: Geographical Reach
5.5: Porter’s Five Forces Analysis
6. COST STRUCTURE ANALYSIS
6.1: Cost of Goods Sold
6.2: SG&A
6.3: EBITDA Margin
7. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
7.1: Growth Opportunity Analysis
7.1.1: Growth Opportunities for the Global Gene Therapy Market by Gene Type
7.1.2: Growth Opportunities for the Global Gene Therapy Market by Application
7.1.3: Growth Opportunities for the Global Gene Therapy Market by Vector
7.1.4: Growth Opportunities for the Global Gene Therapy Market by Indication
7.1.5: Growth Opportunities for the Global Gene Therapy Market by Delivery Method
7.1.6: Growth Opportunities for the Global Gene Therapy Market by Region
7.2: Emerging Trends in the Global Gene Therapy Market
7.3: Strategic Analysis
7.3.1: New Product Development
7.3.2: Capacity Expansion of the Global Gene Therapy Market
7.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Gene Therapy Market
7.3.4: Certification and Licensing
8. COMPANY PROFILES OF LEADING PLAYERS
8.1: Biogen
8.2: Novartis AG
8.3: Gilead Sciences, Inc.
8.4: Spark Therapeutics, Inc.
8.5: MolMed S.p.A
8.6: Orchard Therapeutics plc.
8.7: SIBIONO
8.8: Shanghai Sunway Biotech Co., Ltd.
8.9: Bluebird Bio, Inc.
8.10: Human Stem Cells Institute
2. MARKET BACKGROUND AND CLASSIFICATIONS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2014 T 2025
3.1: Macroeconomic Trends and Forecast
3.2: Global Gene Therapy Market Trends and Forecast
3.3: Global Gene Therapy Market by Gene Type
3.3.1: Antigen
3.3.2: Cytokine
3.3.3: Tumor Suppressor
3.3.4: Suicide
3.3.5: Deficiency
3.3.6: Growth Factors
3.3.7: Receptors
3.3.8: Others
3.4. Global Gene Therapy Market by Application
3.4.1: Oncological Disorders
3.4.2: Rare Diseases
3.4.3: Cardiovascular Diseases
3.4.4: Neurological Disorders
3.4.5: Infectious Disease
3.4.6: Other Diseases
3.5. Global Gene Therapy Market by Vector
3.5.1: Non-Viral Vectors
3.5.1.1: Oligonucleotides
3.5.1.2: Other Non-Viral Vectors
3.5.2: Viral Vectors
3.5.2.1: Retroviral Vectors
3.5.2.2: Adeno-Associated Virus Vectors
3.5.2.3: Other Viral Vectors
3.6. Global Gene Therapy Market by Indication
3.6.1: Neurological Diseases
3.6.2: Cancer
3.6.3: Hepatological Diseases
3.6.4: Duchenne Muscular Dystrophy
3.6.5: Other Indications
3.7. Global Gene Therapy Market by Delivery Method
3.7.1: In Viv Gene Therapy
3.7.2: Ex Viv Gene Therapy
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION
4.1: Global Gene Therapy Market by Region
4.2: North American Gene Therapy Market
4.2.1: Market by Gene Type: Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others
4.2.2: Market byApplication: Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Disease, and Other Diseases
4.2.3: Market by Vector: Non-Viral Vectors (Oligonucleotides and Other Non-Viral Vectors) and Viral Vectors (Retroviral Vectors, Adeno-Associated Virus Vectors, and Other Viral Vectors
4.2.4: Market by Indication: Neurological Diseases, Cancer, Hepatological Diseases, Duchenne Muscular Dystrophy, and Other Indications
4.2.5: Market by Delivery Method: In Viv Gene Therapy and Ex Viv Gene Therapy
4.2.6: The United States Gene Therapy Market
4.2.7: The Canadian Gene Therapy Market
4.2.8: The Mexican Gene Therapy Market
4.3. European Gene Therapy Market
4.3.1: Market by Gene Type: Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others
4.3.2: Market by Application: Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Disease, and Other Diseases
4.3.3: Market by Vector: Non-Viral Vectors (Oligonucleotides and Other Non-Viral Vectors) and Viral Vectors (Retroviral Vectors, Adeno-Associated Virus Vectors, and Other Viral Vectors
4.3.4: Market by Indication: Neurological Diseases, Cancer, Hepatological Diseases, Duchenne Muscular Dystrophy, and Other Indications
4.3.5: Market by Delivery Method: In Viv Gene Therapy and Ex Viv Gene Therapy
4.3.6: The Gene Therapy Market of United Kingdom
4.3.7: The German Gene Therapy Market
4.3.8: The French Gene Therapy Market
4.4. APAC Gene Therapy Market
4.4.1: Market by Gene Type: Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others
4.4.2: Market byApplication: Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Disease, and Other Diseases
4.4.3: Market by Vector: Non-Viral Vectors (Oligonucleotides and Other Non-Viral Vectors) and Viral Vectors (Retroviral Vectors, Adeno-Associated Virus Vectors, and Other Viral Vectors
4.4.4: Market by Indication: Neurological Diseases, Cancer, Hepatological Diseases, Duchenne Muscular Dystrophy, and Other Indications
4.4.5: Market by Delivery Method: In Viv Gene Therapy and Ex Viv Gene Therapy
4.4.6: The Chinese Gene Therapy Market
4.4.7: The Indian Gene Therapy Market
4.4.8: The Japanese Gene Therapy Market
4.5: ROW Gene Therapy Market
4.5.1: Market by Gene Type: Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others
4.5.2: Market by Application: Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Disease, and Other Diseases
4.5.3: Market by Vector: Non-Viral Vectors (Oligonucleotides and Other Non-Viral Vectors) and Viral Vectors (Retroviral Vectors, Adeno-Associated Virus Vectors, and Other Viral Vectors
4.5.4: Market by Indication: Neurological Diseases, Cancer, Hepatological Diseases, Duchenne Muscular Dystrophy, and Other Indications
4.5.5: Market by Delivery Method: In Viv Gene Therapy and Ex Viv Gene Therapy
4.5.6: Brazilian Gene Therapy Market
5. COMPETITOR ANALYSIS
5.1: Market Share Analysis
5.2: Product Portfoli Analysis
5.3: Operational Integration
5.4: Geographical Reach
5.5: Porter’s Five Forces Analysis
6. COST STRUCTURE ANALYSIS
6.1: Cost of Goods Sold
6.2: SG&A
6.3: EBITDA Margin
7. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
7.1: Growth Opportunity Analysis
7.1.1: Growth Opportunities for the Global Gene Therapy Market by Gene Type
7.1.2: Growth Opportunities for the Global Gene Therapy Market by Application
7.1.3: Growth Opportunities for the Global Gene Therapy Market by Vector
7.1.4: Growth Opportunities for the Global Gene Therapy Market by Indication
7.1.5: Growth Opportunities for the Global Gene Therapy Market by Delivery Method
7.1.6: Growth Opportunities for the Global Gene Therapy Market by Region
7.2: Emerging Trends in the Global Gene Therapy Market
7.3: Strategic Analysis
7.3.1: New Product Development
7.3.2: Capacity Expansion of the Global Gene Therapy Market
7.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Gene Therapy Market
7.3.4: Certification and Licensing
8. COMPANY PROFILES OF LEADING PLAYERS
8.1: Biogen
8.2: Novartis AG
8.3: Gilead Sciences, Inc.
8.4: Spark Therapeutics, Inc.
8.5: MolMed S.p.A
8.6: Orchard Therapeutics plc.
8.7: SIBIONO
8.8: Shanghai Sunway Biotech Co., Ltd.
8.9: Bluebird Bio, Inc.
8.10: Human Stem Cells Institute
